Board-certified physician specializing in radioligand therapy for metastatic prostate and neuroendocrine cancers
Residency training in radiation oncology at Yale-New Haven Hospital/Yale School of Medicine
Specialty training at the Nuclear Medicine and Radiomolecular Theranostics Clinic, ENETS Center of Excellence, Zentralklinik, Bad Berka, Germany
Passionate about providing the most optimal, personalized, and state-of-the-art care possible to patients living with cancer
This is an incredibly exciting time in medicine with the emergence of advancing technologies and therapeutics, which provide treatment opportunities for patients that both extend the quantity of life while sustaining quality of life. It is an honor and privilege to be at the forefront of cancer care, helping to bring hope to as many patients and families as possible.
— Brandon R. Mancini, MD, MBA, FACRO
Brandon R. Mancini, MD, MBA, FACRO, serves as medical director at BAMF Health in Grand Rapids, Michigan in the emerging field of theranostics. His primary clinical focus is on the treatment of people with metastatic prostate and neuroendocrine cancers.
Dr. Mancini has also worked as clinical assistant professor at Western Michigan University School of Medicine and sits on multiple committees of the American College of Radiation Oncology (ACRO). From 2016 to 2022, he practiced radiation oncology as well. He has contributed to and published several abstracts, book chapters, and manuscripts in prestigious national and international journals.
Brandon R. Mancini, MD, MBA, FACRO, received his bachelor’s degree from the University of Michigan. Afterward, he went on to earn his medical degree from Wayne State University School of Medicine.
Dr. Mancini then completed an internal medicine internship and residency in therapeutic radiology (radiation oncology) at Yale New Haven Hospital/Yale School of Medicine in New Haven, Connecticut. During the final year of his residency, he served as chief resident.
He also received his Master of Business Administration from Yale School of Management and his Fellow of the American College of Radiation Oncology (FACRO) from the American College of Radiation Oncology.